image
Healthcare - Biotechnology - NASDAQ - US
$ 8.19
-3.87 %
$ 526 M
Market Cap
-19.98
P/E
CASH FLOW STATEMENT
-23.9 M OPERATING CASH FLOW
11.43%
15.5 M INVESTING CASH FLOW
166.77%
7.86 M FINANCING CASH FLOW
0.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Corvus Pharmaceuticals, Inc.
image
Net Income -27 M
Depreciation & Amortization 151 K
Capital Expenditures -34 K
Stock-Based Compensation 2.15 M
Change in Working Capital -3.59 M
Others 685 K
Free Cash Flow -24 M

Cash Flow

Millions
Dec-2023 Dec-2022 Dec-2021 Dec-2020 Dec-2019 Dec-2018 Dec-2017 Dec-2016 Dec-2015 Dec-2014
OPERATING CASH FLOW
Net Income (27.0) (41.3) (43.2) (6.0) (46.7) (46.9) (55.7) (36.4) (31.3) (0.2)
Depreciation & Amortization 0.2 0.4 0.5 0.6 0.7 0.8 0.8 0.6 0.1 0
Deferred Income Tax 0 0 0 0 0 0 0 (3.8) 41 K 0
Stock Based Compensation 2.1 2.7 4.2 5.7 7.3 7.1 6.2 3.8 0.4 0
Other Operating Activities 4.4 9.8 5.1 (37.1) (0.6) (0.6) (0.2) 4.5 17.6 62.2 K
Change in Working Capital (3.6) 1.4 (3.2) 1.9 1.9 (1.4) 2.6 3.4 1.8 8.73 K
Cash From Operations (23.9) (27.0) (36.7) (34.8) (37.3) (41.0) (46.2) (27.9) (11.3) (0.1)
INVESTING CASH FLOW
Capital Expenditures 34 K (0.3) 5 K 76 K 25 K (0.4) (0.3) (2.2) (1.7) 0
Other Items 15.6 (23.0) 21.6 44.8 3.3 (29.8) 85.1 (40.4) (90.3) 0
Cash From Investing Activities 15.5 (23.3) 21.6 44.8 3.3 (30.2) 84.8 (42.6) (92.0) 0
FINANCING CASH FLOW
Common Stock Repurchased 0 0 0 0 0 0 0 0 0 0
Total Debt Repaid 0 0 0 0 0 0 0 0 0 0
Dividends Paid 0 0 0 0 0 0 0 0 0 0
Other Financing Activities 12 K 0 1.2 88 K 24 K 0.4 0.7 4 K 94.9 13.8
Cash From Financing Activities 7.9 0 62.2 1.3 24 K 65.3 1.4 71.4 94.9 13.8
CHANGE IN CASH
Net Change In Cash (0.5) (50.3) 47.0 11.3 (34.0) (5.9) 40.1 0.9 (8.4) 13.7
FREE CASH FLOW
Free Cash Flow (24.0) (27.3) (36.7) (34.9) (37.3) (41.3) (46.5) (30.1) (13.1) (0.1)